Skip to main content
TipRanks
Go Ultimate75% OFF

Immucell (ICCC) AI Stock Analysis

81 Followers
ICCC

Immucell

(NASDAQ:ICCC)

Select Model
Rating:63Neutral
Price Target:$11.00▲(2.33% Upside)
Action:reiterated
Date:11/13/26

ICCC’s score is driven primarily by improving financial performance (better profitability, stronger cash generation, and lower leverage) and a constructive earnings-call backdrop (strong growth and capacity expansion progress). These positives are tempered by a very high P/E valuation and largely neutral technical momentum, keeping the overall rating in the mid-range.

Positive Factors
Strong Revenue and Customer GrowthBroad-based sales and distributor-volume growth indicates stronger product adoption and commercial execution, not merely isolated customer activity. Continued expansion can improve operating leverage, strengthen channel relationships, and provide a durable base for scaling the company’s cattle-health portfolio.
Negative Factors
Thin and Volatile ProfitabilityAlthough the company has returned to profit, modest margins leave limited protection against cost increases or execution setbacks. The history of losses and volatile earnings makes it harder to establish that the recent improvement is durable rather than an early-stage recovery.

Immucell (ICCC) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%175%ICCC+135.75%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$97.63M
Dividend Yield
―
Average Volume (3M)
14.98K
Price to Earnings (P/E)
53.8
Beta (1Y)
0.09
Revenue Growth
19.59%
EPS Growth
-20.08%
Country
US
Employees
73
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Immucell Business Overview & Revenue Model

Company Description

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market...

How the Company Makes Money

ImmuCell makes money by selling animal health products to customers serving the cattle industry (including dairy-focused channels). Its core revenue stream historically has been product sales of its mastitis-related offering(s), sold through establis...

Immucell Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:5.19%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was strongly positive, characterized by 46% third-quarter revenue growth, improved gross margin, a return to profitability, higher manufacturing output, strong distributor and Tri-Shield growth, and progress on capacity expansion. The company also reported challenges, including historical contamination-related supply issues, rising colostrum-sourcing prices, higher operating expenses, and the unsuccessful Re-Tain development program, but these were outweighed by the reported operating and financial improvements.

Positive Updates

Strong Third-Quarter Revenue Growth
Third-quarter 2026 product sales were approximately $8 million, up 46% compared with the third quarter of 2025. Management attributed the increase to restored product availability, a favorable domestic calf market, increased commercial activity, improved supply-chain management, and the absence of distributor restocking headwinds that affected the prior-year quarter.

Negative Updates

Re-Tain Development Halted
The company stopped investing in Re-Tain after its contract manufacturer was unable to obtain GMP approval from the FDA. Recent clinical trials were unsuccessful in supporting incremental or new claims, Re-Tain activities remain paused, and management said it is not planning further investment in the product.

Company Guidance

Management expects calf values to remain strong in 2027 and 2028, believes it can meet customer demand with improved yield management until the new drying capacity expansion project is completed, and expects the new freeze dryer planned for installation in the first half of 2027 to “triple or so” freeze-drying capacity; the liquids processing expansion is expected to be completed by the end of 2027, with the overall project remaining on track to the original $8 million overall budget.

Immucell Financial Statement Overview

Summary

Overall fundamentals are improving: a return to profitability in TTM, solid ~40% gross margin, sharply better operating cash flow ($7.8M) and free cash flow ($5.4M), and meaningfully reduced debt ($5.5M vs. ~$13–15M in prior years). Offsetting this, profitability is still thin (TTM net margin ~2.6%, EBIT margin ~3.8%) and results have been volatile across recent years, so durability of the recovery remains the key risk.

Income Statement

62Positive

Balance Sheet

70Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue33.21M27.64M26.49M17.47M18.57M19.24M
Gross Profit13.56M11.45M7.94M4.40M7.65M8.66M
EBITDA4.48M2.14M1.07M-2.50M349.99K2.70M
Net Income1.88M-1.04M-2.16M-5.77M-2.49M-78.29K
Balance Sheet
Total Assets47.96M42.53M45.10M43.81M44.86M44.47M
Cash, Cash Equivalents and Short-Term Investments7.91M3.81M3.76M978.74K5.79M10.19M
Total Debt12.01M13.19M15.10M16.69M12.48M10.27M
Total Liabilities15.18M15.48M17.58M18.82M14.48M11.89M
Stockholders Equity32.77M27.06M27.52M24.99M30.38M32.58M
Cash Flow
Free Cash Flow5.40M1.22M-107.82K-6.57M-5.52M-1.65M
Operating Cash Flow7.83M2.48M357.90K-4.67M-1.54M954.17K
Investing Cash Flow-2.41M-1.21M-461.23K-1.89M-3.96M-1.60M
Financing Cash Flow-1.39M-1.21M2.88M1.75M1.11M3.88M

Immucell Technical Analysis

Technical Analysis SentimentPositive
Last Price10.75

Price Trends

50DMA10.10Positive
100DMA10.34Positive
200DMA9.05Positive

Market Momentum

MACD0.04Negative
RSI59.43Neutral
STOCH73.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICCC, the sentiment is Positive. The current price of 10.75 is above the 20-day moving average (MA) of 10.32, above the 50-day MA of 10.10, and above the 200-day MA of 9.05, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 59.43 is Neutral, neither overbought nor oversold. The STOCH value of 73.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICCC.

Immucell Risk Analysis

Immucell disclosed 38 risk factors in its most recent earnings report. Immucell reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Risks Pertaining to Common StockQ4, 2023
2.Other RisksQ4, 2023
3.Financial RisksQ4, 2023

Immucell Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ICCC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ICCCICCC63Neutral$97.73M53.756.25%―19.59%-20.08%
INOINO55Neutral$267.85M-1.80-9999.00%―63.93%68.94%
ARCTARCT54Neutral$240.96M-2.70-46.79%―-74.84%-25.04%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
PDSBPDSB42Neutral$91.63M-1.56-679.00%――32.24%
RANIRANI42Neutral$73.40M-2.78-96.44%―448.67%76.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%ICCCINOARCTXBITPDSBRANIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ICCC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ICCCImmucell10.755.84118.94%
INOInovio Pharmaceuticals1.43-0.55-27.78%
ARCTArcturus Therapeutics8.361.6023.67%
XBITXBiotech Inc.1.96-0.51-20.65%
PDSBPds Biotechnology0.870.0912.23%
RANIRani Therapeutics Holdings, Inc. Class A0.53-1.41-72.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026